Serina Therapeutics, Inc.
Income Statement
| Line Item | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5.0K | $3.1M | $29.0K | $7.0K | $30.0K | $8.0K | $9.0K | $12.0K |
| Cost of Revenue | — | $1.0K | $33.0K | $5.0K | $1.0K | $1.0K | $5.0K | $6.0K |
| Gross Profit | — | $55.0K | $34.0K | $4.0K | $9.0K | $7.0K | $4.0K | $6.0K |
| Gross Margin | — | 1.8% | 117.2% | 57.1% | 30.0% | 87.5% | 44.4% | 50.0% |
| Operating Expenses | ||||||||
| Research & Development | $1.1M | $907.0K | $603.0K | $479.0K | $399.0K | $208.0K | $162.0K | $259.0K |
| SG&A Expense | $1.2M | $1.9M | $889.0K | $473.0K | $593.0K | $1.6M | $1.4M | $1.3M |
| Operating Income | $-2.3M | $241.0K | $-1.5M | $-945.0K | $-962.0K | $-1.8M | $-1.6M | $-1.6M |
| Operating Margin | -46,420.0% | 7.8% | -5,044.8% | -13,500.0% | -3,206.7% | -22,275.0% | -17,222.2% | -13,258.3% |
| Interest Expense | $99.0K | $986.0K | $3.0M | $792.0K | $86.0K | $978.0K | $923.0K | $863.0K |
| Pretax Income | — | — | — | — | — | $18.3M | $-2.4M | $-2.6M |
| Income Tax Expense | — | $0 | $0 | $0 | $0 | — | $0 | $0 |
| Net Income | $-15.0M | $1.1M | $1.8M | $808.0K | $1.7M | $-2.7M | $-2.4M | $-2.6M |
| Net Margin | -300,300.0% | 34.0% | 6,041.4% | 11,542.9% | 5,526.7% | -33,787.5% | -27,055.6% | -21,816.7% |
| EPS (Basic) | $-5.38 | $0.42 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| EPS (Diluted) | $-5.38 | $0.19 | $0.00 | $0.00 | $0.00 | — | $0.00 | $0.00 |
| Shares Outstanding (Basic) | 2.8M | 2.2M | 14.92B | 14.80B | 14.76B | 258.52B | 258.53B | 258.51B |
| Shares Outstanding (Diluted) | 2.8M | — | 51.67B | — | 58.38B | 7.4M | 258.5M | 258.5M |
| Dividends Per Share | — | — | — | — | — | — | — | — |